[go: up one dir, main page]

ES2117642T3 - Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles. - Google Patents

Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.

Info

Publication number
ES2117642T3
ES2117642T3 ES91909922T ES91909922T ES2117642T3 ES 2117642 T3 ES2117642 T3 ES 2117642T3 ES 91909922 T ES91909922 T ES 91909922T ES 91909922 T ES91909922 T ES 91909922T ES 2117642 T3 ES2117642 T3 ES 2117642T3
Authority
ES
Spain
Prior art keywords
active substance
biologically active
mammal
pharmaceutical composition
mucosal membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909922T
Other languages
English (en)
Inventor
Erik Bechgaard
Sveinbjorn Gizurarson
Rolf Kuhlman Hjortkjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bechgaard International Research and Development AS
Original Assignee
Bechgaard International Research and Development AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK117090A external-priority patent/DK117090D0/da
Priority claimed from DK207590A external-priority patent/DK207590D0/da
Application filed by Bechgaard International Research and Development AS filed Critical Bechgaard International Research and Development AS
Application granted granted Critical
Publication of ES2117642T3 publication Critical patent/ES2117642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

UNA PREPARACION FARMACEUTICA PARA APLICACION DE UNA SUSTANCIA, O SUSTANCIAS, BIOLOGICAMENTE ACTIVA A UNA MEMBRANA MUCOSA DE UN MAMIFERO QUE COMPRENDE UNA O MAS SUSTANCIAS SELECCIONADAS DEL GRUPO CONSISTENTE EN N LA FORMULA (I), DONDE N ES 1 A 8, Y N PRESENTADOS POR LA FORMULA (II): H(OCH2CH2)POH, DONDE P ES 1 A 14, PRODUCE UNA CONCENTRACION DE PLASMA ALTA DE LA SUSTANCIA O SUSTANCIAS FARMACEUTICAMENTE ACTIVA CASI TAN RAPIDA COMO LA ADMINISTRACION INTRAVENOSA.
ES91909922T 1990-05-10 1991-05-03 Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles. Expired - Lifetime ES2117642T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK117090A DK117090D0 (da) 1990-05-10 1990-05-10 Composition for intranasal administration of biol ogically active benzodiazepine compounds
DK207590A DK207590D0 (da) 1990-08-30 1990-08-30 Farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
ES2117642T3 true ES2117642T3 (es) 1998-08-16

Family

ID=26065326

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909922T Expired - Lifetime ES2117642T3 (es) 1990-05-10 1991-05-03 Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.

Country Status (14)

Country Link
US (2) US5428006A (es)
EP (1) EP0532546B1 (es)
JP (1) JP3219096B2 (es)
CN (1) CN1056812A (es)
AT (1) ATE164080T1 (es)
AU (3) AU7880991A (es)
CS (1) CS136191A3 (es)
DE (1) DE69129110T2 (es)
DK (1) DK0532546T3 (es)
ES (1) ES2117642T3 (es)
IE (1) IE911577A1 (es)
IL (1) IL98089A0 (es)
PT (1) PT97610A (es)
WO (1) WO1991016929A1 (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129110T2 (de) * 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
NZ246137A (en) 1991-12-19 1996-04-26 Univ Saskatchewan Mature desiccation tolerant gymnosperm somatic embryos and their production
GB2267435A (en) * 1992-06-01 1993-12-08 British Tech Group Factor VIII
EP0661989B1 (en) * 1992-09-21 1997-08-06 PHARMACIA & UPJOHN COMPANY Sustained-release protein formulations
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
EP0621033A1 (en) * 1993-04-20 1994-10-26 Nostras S.A. Antibiotic composition containing oxytetracycline and glycofurol
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
ATE214289T1 (de) * 1993-10-21 2002-03-15 Hisamitsu Pharmaceutical Co Pernasale zusammensetzung und diese enthaltende pernasale zubereitung
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CZ288146B6 (en) 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
TR199700834T1 (xx) * 1995-02-22 1998-01-21 Novartis Ag 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5942499A (en) * 1996-03-05 1999-08-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US5869082A (en) * 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE69738333T2 (de) * 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6391282B1 (en) * 1997-11-10 2002-05-21 Flemington Pharmaceutical Corp. Antihistamine sprays and ointments for relief of delayed contact dermatitis
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
EP1189596A1 (de) * 1999-06-02 2002-03-27 Norbert Dr.med. Klöcker Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen
JP2004525854A (ja) * 1999-06-02 2004-08-26 ヘキサル・アクチェンゲゼルシャフト 水中に不溶性及び／又は難溶性である活性物質の鼻腔内投与用薬剤組成物
CA2375914A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ATE393626T1 (de) * 1999-07-26 2008-05-15 Sk Holdings Co Ltd Transnasale anticonvulsive zusammensetzungen
FR2796843B1 (fr) * 1999-07-29 2003-05-09 So Ge Val Sa Composition antipyretique concentree et stabilisee a usage veterinaire destine a etre incorporee a l'alimentation des animaux ainsi que procede d'incorporation de cette composition a l'eau de boisson d'animaux
KR100619612B1 (ko) 1999-10-04 2006-09-01 넥타르 테라퓨틱스 에이엘, 코포레이션 폴리머 안정화 신경펩타이드
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
AU772029B2 (en) * 2000-03-08 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
DK1307194T4 (da) * 2000-07-31 2011-07-18 Nycomed Danmark Aps Fentanylpræparat til nasal administration
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
JP4464129B2 (ja) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル，リミティド ナノ粒子インスリン製剤
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
WO2003051281A2 (en) * 2001-10-17 2003-06-26 Ganado Research, L.L.C. Composition and method to treat viral bacterial and parasitic infections and infestations
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
CA2520775A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
WO2004110403A1 (en) * 2003-06-17 2004-12-23 Sk Corporation Transnasal microemulsions containing diazepam
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US7713935B2 (en) * 2004-10-01 2010-05-11 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compounds that modulate TRH actions
PL1848419T3 (pl) * 2005-02-01 2012-12-31 Troikaa Pharmaceuticals Ltd Preparaty diklofenaku i jego farmaceutycznie dopuszczalnych soli do wstrzykiwań
CA2597956C (en) 2005-02-17 2013-07-09 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
DK2001518T3 (da) * 2006-03-30 2013-10-07 Palatin Technologies Inc Cykliske natriuretiske peptidfremstillinger
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
HUE031463T2 (en) 2007-01-19 2017-07-28 Hananja Ehf Method and compositions for administering an active ingredient
EP2152247A4 (en) * 2007-05-10 2012-12-26 Novadel Pharma Inc COMPOSITIONS AND METHODS ANTI-INSOMNIA
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
BRPI0815782A2 (pt) * 2007-08-31 2015-02-24 Archimedes Dev Ltd Composição para a dispensação intranasal de uma droga, uso de uma composição não aquosa, dispositivo para a dispensação nasal de drogas ou um cartucho de dose, usos de um veículo, não aquoso, e de uma droga de benzodiazepina e um veículo não aquoso
US8507468B2 (en) 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8473062B2 (en) * 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2720699B1 (en) * 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP3194422B1 (en) 2014-09-19 2020-04-29 Tensive Controls, Inc. Anti-microbial peptides
MX389178B (es) 2014-12-12 2025-03-20 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CA3064840A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CA3165355A1 (en) 2020-02-18 2021-07-22 Tommy SANDER Pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) * 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
HU190841B (en) * 1983-02-04 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for the production of cyclodextrin polymers swelling in water quickly and to a high extent
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0278997A1 (de) * 1987-02-17 1988-08-24 Siegfried Aktiengesellschaft Azapropazon-Rektalkapseln
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
DE3939492A1 (de) * 1989-11-29 1991-06-06 Mack Chem Pharm Pharmazeutische zubereitungen
DE69129110T2 (de) * 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole

Also Published As

Publication number Publication date
IE911577A1 (en) 1991-11-20
US5693608A (en) 1997-12-02
US5428006A (en) 1995-06-27
AU654950B2 (en) 1994-12-01
DK0532546T3 (da) 1998-12-28
AU1358695A (en) 1995-06-01
JP3219096B2 (ja) 2001-10-15
CS136191A3 (en) 1992-04-15
DE69129110T2 (de) 1998-12-10
DE69129110D1 (de) 1998-04-23
JPH05507085A (ja) 1993-10-14
IL98089A0 (en) 1992-06-21
PT97610A (pt) 1992-01-31
EP0532546B1 (en) 1998-03-18
EP0532546A1 (en) 1993-03-24
AU687496B2 (en) 1998-02-26
ATE164080T1 (de) 1998-04-15
WO1991016929A1 (en) 1991-11-14
AU7880991A (en) 1991-11-27
CN1056812A (zh) 1991-12-11
AU7643591A (en) 1991-11-14

Similar Documents

Publication Publication Date Title
ES2117642T3 (es) Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
FR2512670B1 (fr) Capsules contenant le principe actif d'un allergene et procede pour leur preparation
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
JPS6470415A (en) Skin permeable remedy system
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
ATE55248T1 (de) Arzneimittelkombination.
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
ATE8739T1 (de) Pharmazeutische zubereitungen.
KR890012942A (ko) 5-치환된 오르니틴 유도체
DE69531166D1 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
KR900701278A (ko) 바이러스 감염 치료용 담즙산
ATE24398T1 (de) Arzneimittelformulierung zur oralen verabreichung mit gehalt an einem glycosid antibiotikum und einem hilfsstoff.
KR880004810A (ko) 소화성 궤양 치료제
EP0753309A2 (en) Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 532546

Country of ref document: ES